The National Cancer Institute, part of the National Institutes of Health, is considering giving Iovance Biotherapeutics, Inc. an exclusive patent license. This license would allow Iovance to develop and sell specific cancer treatment products using a patented method involving engineered cells that could improve anti-tumor action. Interested parties have until March 12, 2021, to submit comments or objections. This license could cover worldwide rights and mainly focuses on treating several types of cancers, excluding certain specific methods.
Simple Explanation
The government is thinking about giving a special permission to a company called Iovance to use smart cells that might help fight cancer. Other people have until March 12, 2021, to say if they think this is a good or bad idea.